losartan has been researched along with alpha-L-Iduronidase Deficiency in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gonzalez, EA | 2 |
| Tobar Leitão, SA | 1 |
| Soares, DDS | 1 |
| Tavares, AMV | 1 |
| Giugliani, R | 2 |
| Baldo, G | 2 |
| Matte, U | 2 |
| Osborn, MJ | 1 |
| Webber, BR | 1 |
| McElmurry, RT | 1 |
| Rudser, KD | 1 |
| DeFeo, AP | 1 |
| Muradian, M | 1 |
| Petryk, A | 1 |
| Hallgrimsson, B | 1 |
| Blazar, BR | 1 |
| Tolar, J | 1 |
| Braunlin, EA | 1 |
| Tavares, AM | 1 |
| Poletto, E | 1 |
3 other studies available for losartan and alpha-L-Iduronidase Deficiency
| Article | Year |
|---|---|
Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodeling.
Topics: Animals; Disease Models, Animal; Echocardiography; Female; Heart Diseases; Iduronidase; Losartan; Ma | 2021 |
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
Topics: Angiotensin Receptor Antagonists; Animals; Craniofacial Abnormalities; Disease Models, Animal; Femal | 2017 |
Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I.
Topics: Aortic Diseases; Cardiovascular Diseases; Dilatation; Humans; Losartan; Mucopolysaccharidosis I | 2017 |